CONVENTION ON INTERNATIONAL TRADE IN ENDANGERED SPECIES OF WILD FAUNA AND FLORA

Twenty-fifth meeting of the Plants Committee
Online, 2-4, 21 and 23 June 2021

TRADE IN MEDICINAL AND AROMATIC PLANT SPECIES

Membership (as decided by the Committee)

Members: representatives for Africa (Ms. Khayota and Mr. Mahamane), representative for North America (Ms. Gnam) (Chair);

Parties: Argentina, Cambodia, Canada, China, Georgia, Germany, Kenya, Malaysia, Republic of Korea, Singapore, United Kingdom of Great Britain and Northern Ireland, and United States of America; and


Mandate

The in-session working group shall:

a) consider the draft decisions in the Annex to the addendum, taking into account progress reported in document PC25 Doc. 30 and its addendum, and information document CoP18 Inf. 11; and

b) make any additional recommendations for the Plants Committee to consider.

Recommendations

The working group recommends that the Plants Committee agree to submit the following draft decisions on medicinal and aromatic plant species to the Conference of the Parties (text proposed to be deleted are in strikethrough and proposed new text is underlined):

Directed to the Secretariat

19.AA The Secretariat shall, in close collaboration with the Plants Committee:

a) develop informational materials for raising awareness of CITES regulations for the medicinal and aromatic plant industry stakeholders and consumers;

b) publish a notification to ask Parties to:

i) liaise with key stakeholders along medicinal and aromatic plant trade value chains, including consumers, to enhance awareness of CITES regulations among key stakeholders, and to reduce demand for unsustainably harvested and traded medicinal plant products; encourage sustainable use and legal trade CITES-listed medicinal and aromatic plants; and
ii) review their non-detriment findings (NDFs) for medicinal and aromatic plants and consider sharing such with the Secretariat to be included on the NDF page of the CITES website;

bc) subject to external funding, commission an in-depth analysis of e-commerce value chains in products of CITES-listed medicinal and aromatic plant species, including a stakeholder analysis of key producers, intermediate traders, manufacturers or distribution platforms to end consumers, and of institutions influencing the demand for CITES-regulated medicinal and aromatic plant products in biomedical, traditional and alternative medical systems, cosmetic and personal care, food industries (as appropriate), and including an assessment whether existing annotations focus on first products in trade or main products in trade;

d) assess the possibilities of using the Medicinal Plant Names Service (MPNS) database in the analysis as per Decision 19.AA, paragraph bc), and invite Parties representing different regions, cultures, and languages, through a notification, to assess the utility of the MPNS database in their routine work to see if it can contribute to the expansion of the Species+ database;

e) review the Resolution Conf. 10.19 (Rev. CoP14) on Traditional medicines in relation to medicinal and aromatic plants and make suggestions as appropriate; and

df) report to the Plants Committee.

**Directed to Parties**

19.BB Parties representing different regions, cultures, and languages are invited to:

a) liaise with key stakeholders along medicinal and aromatic plant trade value chains, including consumers as per Decision 19.AA, paragraph b), to enhance awareness of CITES regulations and to encourage sustainable use and legal trade in medicinal and aromatic plants; and

b) assess the utility of the Medicinal Plant Names Service database in their routine work to see if it can contribute to the expansion of the Species+ database, and to provide feedback to the Plants Committee regarding the Decision 19.AA, paragraph d).

**Directed to the Plants Committee**

19.CC The Plants Committee shall:

a) inform and review the report of the Secretariat as per Decision 19.AA, and the feedback from Parties regarding the utility of the Medicinal Plant Names Service as per Decision 19.BB;

b) taking into consideration the information in document PC25 Doc. 30, information document CoP18 Inf. 11, the report of the Secretariat as per Decision 19.AA, and other relevant information, and in consultation with the Animals Committee, as appropriate, undertake a review of Resolution Conf. 10.19 (Rev. CoP14) on Traditional medicines, and prepare recommendations for a revised Resolution on traditional medicines or a new Resolution on plant-based medicinal products; and

c) make submit its recommendations to the Standing Committee and or the Conference of the Parties, as appropriate.

**Directed to the Standing Committee**

19.DD The Standing Committee shall review any report from the Plants Committee as per Decision 19.CC, as appropriate, and make recommendations, as appropriate, to the Conference of the Parties.